Phase IA/II, multicentre, open-label study of the CD40 antagonistic monoclonal antibody lucatumumab in adult patients with advanced non-Hodgkin or Hodgkin lymphoma

British Journal of Haematology

Volumn 164, Issue 2, 2014, Pages 258-265

  Fanale, Michelle ^a   Assouline, Sarit ^b   Kuruvilla, John ^c   Solal Céligny, Philippe ^d   Heo, Dae S ^e   Verhoef, Gregor ^f   Corradini, Paolo ^g   Abramson, Jeremy S ^h   Offner, Fritz ⁱ   Engert, Andreas ^j   Dyer, Martin J S ^k   Carreon, Daniel ^l   Ewald, Brett ^l   Baeck, Johan ^l   Younes, Anas ^m   Freedman, Arnold S ⁿ  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b MCGILL UNIVERSITY   (Canada)

^c PRINCESS MARGARET HOSPITAL   (Canada)

^d Institut de Cancérologie de l'Ouest ^*  (France)

^e Seoul National University College of Medicine   (South Korea)

^f UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^g UNIVERSITY OF MILAN   (Italy)

^h MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

ⁱ GHENT UNIVERSITY HOSPITAL   (Belgium)

^j UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^k UNIVERSITY OF LEICESTER   (United Kingdom)

^l NOVARTIS PHARMA AG   (Switzerland)

^m MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

ⁿ DANA FARBER CANCER INSTITUTE   (United States)

more..

Author keywords

Hodgkin lymphoma; Monoclonal antibodies; Non Hodgkin lymphoma

Indexed keywords

LUCATUMUMAB; TRIACYLGLYCEROL LIPASE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; ASTHENIA; BACKACHE; CANCER RECURRENCE; CHILL; CONSTIPATION; COUGHING; DIARRHEA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FATIGUE; FEMALE; FEVER; FOLLICULAR LYMPHOMA; HEADACHE; HODGKIN DISEASE; HUMAN; HYPOTENSION; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MANTLE CELL LYMPHOMA; MARGINAL ZONE LYMPHOMA; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NONHODGKIN LYMPHOMA; PERIPHERAL EDEMA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT OUTCOME; VERY ELDERLY; VOMITING; YOUNG ADULT;

HODGKIN LYMPHOMA; MONOCLONAL ANTIBODIES; NON-HODGKIN LYMPHOMA;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIGENS, CD40; ANTINEOPLASTIC AGENTS; FEMALE; HODGKIN DISEASE; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; NEOPLASM STAGING; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84891626501     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12630     Document Type: Article

References (27)

1. Advani, R., Forero-Torres, A., Furman, R.R., Rosenblatt, J.D., Younes, A., Ren, H., Harrop, K., Whiting, N. & Drachman, J.G. (2009) Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's lymphoma. Journal of Clinical Oncology, 27, 4371-4377.
2. Aldinucci, D., Gloghini, A., Pinto, A., Colombatti, A. & Carbone, A. (2012) The role of CD40/CD40L and interferon regulatory factor 4 in Hodgkin lymphoma microenvironment. Leukemia & Lymphoma, 53, 195-201.
3. Babb, J., Rogatko, A. & Zacks, S. (1998) Cancer phase I clinical trials: efficient dose escalation with overdose control. Statistics in Medicine, 17, 1103-1120.
4. Beatty, G.L., Chiorean, E.G., Fishman, M.P., Saboury, B., Teitelbaum, U.R., Sun, W., Huhn, R.D., Song, W., Li, D. & Sharp, L.L. (2011) CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science, 331, 1612-1616.
5. Bensinger, W., Maziarz, R.T., Jagannath, S., Spencer, A., Durrant, S., Becker, P.S., Ewald, B., Bilic, S., Rediske, J., Baeck, J. & Stadtmauer, E.A. (2012) A phase 1 study of lucatumumab, a fully human anti-CD40 antagonist monoclonal antibody administered intravenously to patients with relapsed or refractory multiple myeloma. British Journal of Haematology, 159, 58-66.
6. Biancone, L., Cantaluppi, V. & Camussi, G. (1999) CD40-CD154 interaction in experimental and human disease (review). International Journal of Molecular Medicine, 3, 343-353.
7. Burington, B., Yue, P., Shi, X., Advani, R., Lau, J.T., Tan, J., Stinson, S., Stinson, J., Januario, T., de Vos, S., Ansell, S., Forero-Torres, A., Fedorowicz, G., Yang, T.T., Elkins, K., Du, C., Mohan, S., Yu, N., Modrusan, Z., Seshagiri, S., Yu, S.F., Pandita, A., Koeppen, H., French, D., Polson, A.G., Offringa, R., Whiting, N., Ebens, A. & Dornan, D. (2011) CD40 pathway activation status predicts response to CD40 therapy in diffuse large B cell lymphoma. Science Translational Medicine, 3, 74ra22.
8. Byrd, J.C., Kipps, T.J., Flinn, I.W., Cooper, M., Odenike, O., Bendiske, J., Rediske, J., Bilic, S., Dey, J., Baeck, J. & O'Brien, S. (2012) Phase I study of the anti-CD40 humanized monoclonal antibody lucatumumab (HCD122) in relapsed chronic lymphocytic leukemia. Leukemia & Lymphoma, 53, 2136-2142.
9. Carbone, A., Gloghini, A., Gruss, H.J. & Pinto, A. (1995a) CD40 antigen expression on Reed-Sternberg cells. A reliable diagnostic tool for Hodgkin's disease. The American Journal of Pathology, 146, 780-781.
10. Carbone, A., Gloghini, A., Gattei, V., Aldinucci, D., Degan, M., De Paoli, P., Zagonel, V. & Pinto, A. (1995b) Expression of functional CD40 antigen on Reed-Sternberg cells and Hodgkin's disease cell lines. Blood, 85, 780-789.
11. Cheson, B.D., Pfistner, B., Juweid, M.E., Gascoyne, R.D., Specht, L., Horning, S.J., Coiffier, B., Fisher, R.I., Hagenbeek, A., Zucca, E., Rosen, S.T., Stroobants, S., Lister, T.A., Hoppe, R.T., Dreyling, M., Tobinai, K., Vose, J.M., Connors, J.M., Federico, M., Diehl, V. & International Harmonization Project on Lymphoma. (2007) Revised response criteria for malignant lymphoma. Journal of Clinical Oncology, 25, 579-586.
12. Dotan, E., Aggarwal, C. & Smith, M.R. (2010) Impact of rituximab (Rituxan) on the treatment of B-cell non-Hodgkin's lymphoma. P & T: A Peer-Reviewed Journal for Formulary Management, 35, 148-157.
13. Fayad, L., Ansell, S., Advani, R., Coiffier, B., Bartlett, N.L., Stuart, R., Forero-Torres, A., Kuliczkowski, K. & Drachman, J.G. (2011) A phase 2B trial comparing dacetuzumab + R-ICE vs placebo + R-ICE in patients with relapsed diffuse large B-cell lymphoma. Annals of Oncology, 22(Suppl. 4), 145.
14. Fisher, R.I., LeBlanc, M., Press, O.W., Maloney, D.G., Unger, J.M. & Miller, T.P. (2005) New treatment options have changed the survival of patients with follicular lymphoma. Journal of Clinical Oncology, 23, 8447-8452.
15. Forero-Torres, A., Bartlett, N., Beaven, A., Myint, H., Nasta, S., Northfelt, D.W., Whiting, N.C., Drachman, J.G., Lobuglio, A.F. & Moskowitz, C.H. (2013) Pilot study of dacetuzumab in combination with rituximab and gemcitabine for relapsed or refractory diffuse large B-cell lymphoma. Leukemia & Lymphoma, 54, 277-283.
16. Gough, K., Hutchison, M., Keene, O., Byrom, B., Ellis, S., Lacey, L. & McKellar, J. (1995) Assessment of dose proportionality: report from the statisticians in the Pharmaceutical Industry/Pharmacokinetics UK joint working party. Drug Information Journal, 29, 1039-1048.
17. Gruss, H.J. & Dower, S.K. (1995) Tumor necrosis factor ligand superfamily: involvement in the pathology of malignant lymphomas. Blood, 85, 3378-3404.
18. van Kooten, C. & Banchereau, J. (2000) CD40-CD40 ligand. Journal of Leukocyte Biology, 67, 2-17.
19. Lewis, T.S., McCormick, R.S., Emmerton, K., Lau, J.T., Yu, S.F., McEarchern, J.A., Grewal, I.S. & Law, C.L. (2011) Distinct apoptotic signaling characteristics of the anti-CD40 monoclonal antibody dacetuzumab and rituximab produce enhanced antitumor activity in non-Hodgkin lymphoma. Clinical Cancer Research, 17, 4672-4681.
20. Luqman, M., Klabunde, S., Lin, K., Georgakis, G.V., Cherukuri, A., Holash, J., Goldbeck, C., Xu, X., Kadel, E.E., Lee, S.H., Aukerman, S.L., Jallal, B., Aziz, N., Weng, W., Wierda, W., O'Brien, S. & Younes, A. (2008) The antileukemia activity of a human anti-CD40 antagonist antibody, HCD122, on human chronic lymphocytic leukemia cells. Blood, 112, 711-720.
21. Polo, J.M., Ci, W., Licht, J.D. & Melnick, A. (2008) Reversible disruption of BCL6 repression complexes by CD40 signaling in normal and malignant B cells. Blood, 112, 644-651.
22. Schoenberger, S.P., Toes, R.E., van der Voort, E.I., Offringa, R. & Melief, C.J. (1998) T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature, 393, 480-483.
23. Smith, B.P., Vandenhende, F.R., DeSante, K.A., Farid, N.A., Welch, P.A., Callaghan, J.T. & Forgue, S.T. (2000) Confidence interval criteria for assessment of dose proportionality. Pharmaceutical Research, 17, 1278-1283.
24. Swerdlow, S.H., Campo, E., Harris, N.L., Jaffe, E.S., Pileri, S.A., Stein, H., Thiele, J. & Vardiman, J.W. (2008) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th edn. IARC Press, Lyon, France.
25. Thall, P.F., Wathen, J.K., Bekele, B.N., Champlin, R.E., Baker, L.H. & Benjamin, R.S. (2003) Hierarchical bayesian approaches to phase II trials in diseases with multiple subtypes. Statistics in Medicine, 22, 763-780.
26. Uckun, F.M., Gajl-Peczalska, K., Myers, D.E., Jaszcz, W., Haissig, S. & Ledbetter, J.A. (1990) Temporal association of CD40 antigen expression with discrete stages of human B-cell ontogeny and the efficacy of anti-CD40 immunotoxins against clonogenic B-lineage acute lymphoblastic leukemia as well as B-lineage non-Hodgkin's lymphoma cells. Blood, 76, 2449-2456.
27. Vonderheide, R.H., Flaherty, K.T., Khalil, M., Stumacher, M.S., Bajor, D.L., Hutnick, N.A., Sullivan, P., Mahany, J.J., Gallagher, M., Kramer, A., Green, S.J., O'Dwyer, P.J., Running, K.L., Huhn, R.D. & Antonia, S.J. (2007) Clinical activity and immune modulation in cancer patients treated with CP-870, 893, a novel CD40 agonist monoclonal antibody. Journal of Clinical Oncology, 25, 876-883.